Condition (MeSH)
Measles
ClinicalTrials.gov lists 125 trials for Measles or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 23.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
124 of the 125 trials are tagged with Measles itself; the rest are tagged with a narrower condition beneath it.
When did Measles trials start? (31)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 7 |
| 2024 | 6 |
| 2023 | 5 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 5 |
Showing 10 of 31 earlier years.
No forecast is made for this condition: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Measles trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 12 |
| Phase 2/3 | 3 |
| Phase 3 | 40 |
| Phase 4 | 23 |
| Not applicable | 17 |
| Observational | 25 |
How many Measles trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 89 |
| Terminated | 4 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Measles trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 23 |
| Merck Sharp & Dohme LLC | 19 |
| Sanofi Pasteur, a Sanofi Company | 6 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Centers for Disease Control and Prevention | 3 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Measles? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Measles Vaccine (MV) | 9 |
| VARIVAX | 6 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| M-M-R II | 8 |
| Priorix | 6 |
| ProQuad | 6 |
| Havrix+Havrix | 5 |
| Comparator: M-M-R II | 5 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Measles trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastroenteritis | 149 | 25 |
| Pneumonia | 109 | 22 |
| Febrile convulsion | 106 | 21 |
| Bronchiolitis | 80 | 16 |
| Bronchitis | 66 | 9 |
Showing 5 of 10 adverse events.
Which publications cover Measles? (158)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children. | Vaccine | 2025 | Yes |
| Measles neutralising antibody levels in patients receiving intravenous immunoglobulin treatment - a sub-analysis of a randomized, cross-over bioequivalence trial. | PloS one | 2025 | Yes |
| Measles-mumps-rubella-vaccination at 6 months of age induces measles-specific T cell responses: a randomized controlled trial. | Frontiers in immunology | 2025 | Yes |
| Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial. | The Lancet. Child & adolescent health | 2025 | Yes |
| Investigating immune amnesia after measles virus infection in two West African countries: A study protocol. | PloS one | 2025 | Yes |
Showing 5 of 158 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.